MedTrace Logo

Expanded Access Study of UC-MSC in DMD Patients

NCT06579352 · Status: AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2024-08-30

No results posted yet for this study

Summary

The primary objective of this study is to provide UC-MSC treatment to patients with DMD.

Secondary objectives will be to further evaluate treatment-related adverse events as well as changes in DMD-related functional testing/assessments, blood laboratories, and inflammation related biomarker levels over time.

Conditions

Interventions

BIOLOGICAL

Human Umbilical Cord Mesenchymal Stem Cells (UC-MSC)

Umbilical cord-derived mesenchymal stem cells administered intravenously.

Sponsors & Collaborators

  • Signature Biologics

    collaborator UNKNOWN

  • MED Institute Inc.

    lead INDUSTRY

Eligibility

Min Age
5 Years
Max Age
10 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06579352 on ClinicalTrials.gov